2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…2019 American Transplant Congress
Recipient Sex Interacts with Primary Diagnosis to Affect Liver Transplant Graft Survival
1Surgery, University of Colorado, Denver, CO, 2Surgery, Lahey Clinic, Burlington, MA
*Purpose: While recipient sex is a commonly studied risk factor in liver transplantation, findings have been contradictory. We hypothesized that different causes of liver disease…2019 American Transplant Congress
Long-Term Efficacy of Direct-Acting Antiviral Agents
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Long-term efficacy of direct-acting antiviral agents (DAAs) therapy in kidney transplant recipients was unknown. Thus, we aimed to evaluate it in a Chinese cohort…2019 American Transplant Congress
Ready for Prime Time: Intentional Allocation of Hepatitis C Positive Livers into Hepatitis C Negative Recipients
*Purpose: The current discrepancy between supply and demand of liver grafts has dramatically increased the waiting time and mortality on the waiting list. The recent…2019 American Transplant Congress
Trends in Utilization of Deceased Donor Kidneys Based on Donor Hep C Antibody and Nucleic Acid Status
*Purpose: HCV nucleic acid testing (NAT) testing for deceased donors (DD) has been routine since 2015. We intended to look at utilization/discard rates based on…2019 American Transplant Congress
Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. We…2019 American Transplant Congress
Preliminary Results from a Multicenter National Trial of Antiviral-Facilitated Transplantation of Hepatitis C Hearts to Expand the Donor Pool
Baylor University Medical Center, Dallas, TX
*Purpose: Solid organs from donors with evidence of active HCV viremia are historically underutilized particularly for HCV negative recipients. The development of easily tolerated, oral,…2019 American Transplant Congress
Predictors of Glomerular Filtration Rate after Renal Transplantation
Montefiore Medical Center, Bronx, NY
*Purpose: Glomerular filtration rate (GFR) is an excellent indicator of renal function however there is limited data on the impact of KDPI on long term…2019 American Transplant Congress
Transplantation of Hepatitis C Virus Positive Donor Kidneys into Hepatitis C Negative Older Recipients
*Purpose: Patients awaiting transplantation are often at risk of developing life-threatening disease and complications. Older patients have a disproportionately higher risk of dropping out of…2019 American Transplant Congress
Reduction in Waitlist Time Using HCV Positive Liver Grafts in HCV Negative Recipients
Ochsner Health System, New Orleans, LA
*Purpose: With direct-acting antiviral (DAA) therapy, we feel that HCV+ organs are safe for all patients regardless of their HCV status and have adopted a…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 28
- Next Page »